All Stories

  1. The Effects of Bariatric Surgery on Pharmacokinetics of Drugs: a Review of Current Evidence
  2. Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges
  3. Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights Into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges
  4. Diagnostic and Prognostic Value of Serum Omentin-1 in Sepsis: A Prospective Study in Critically Ill Patients
  5. The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives
  6. Perspectives and Challenges of COVID-19 with Obesity-Related Cancers
  7. Could exercise hormone irisin be a therapeutic agent against Parkinson’s and other neurodegenerative diseases?
  8. The Antioxidant Potential of the Mediterranean Diet as a Predictor of Weight Loss after a Very Low-Calorie Ketogenic Diet (VLCKD) in Women with Overweight and Obesity
  9. The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
  10. Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes
  11. Effect of the Implementation of a Structured Diet Management Plan on the Severity of Obstructive Sleep Apnea: A Systematic Review
  12. Regression of common viral warts in an immunocompetent child and an immunosuppressed adult relative after mRNA BNT162b2 COVID‐19 vaccine
  13. Could inhaled corticosteroids be the game changers in the prevention of severe COVID-19? A review of current evidence
  14. SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand?
  15. Drug survival of brodalumab is greater in patients with psoriasis and psoriatic arthritis in a real‐world setting
  16. A chromatin remodeling checkpoint of diet-induced macrophage activation in adipose tissue
  17. Of mice and men: Considerations on adipose tissue physiology in animal models of obesity and human studies
  18. Phase separation may drive mitochondrial nucleoid compartmentation
  19. Use of adenovirus type-5 vector vaccines in COVID-19: potential implications for metabolic health?
  20. Highlighting the Role of Obesity and Insulin Resistance in Type 1 Diabetes and Its Associated Cardiometabolic Complications
  21. Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives
  22. Chlormethine Gel is Efficient and Safe in Mycosis Fungoides Skin Lesions
  23. Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
  24. Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives
  25. Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges
  26. Obesity, Hypovitaminosis D, and COVID-19: the Bermuda Triangle in Public Health
  27. The Efficacy and Safety of Ketogenic Diets in Drug-Resistant Epilepsy in Children and Adolescents: a Systematic Review of Randomized Controlled Trials
  28. DRAK2-SRSF6-regulated RNA alternative splicing is a promising therapeutic target in NAFLD/NASH
  29. Gut mycobiome as a promising preventive and therapeutic target for metabolic disorders
  30. Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2
  31. SARS-CoV-2 adipose tissue infection and hyperglycemia: A further step towards the understanding of severe COVID-19
  32. Nutritional Deficiencies Before and After Bariatric Surgery: Prevention and Treatment
  33. Circulating Chemerin and Its Kinetics May Be a Useful Diagnostic and Prognostic Biomarker in Critically Ill Patients with Sepsis: A Prospective Study
  34. The Impact of the Rate of Weight Loss on Body Composition and Metabolism
  35. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives
  36. A Narrative Review of the Safety of Anti-COVID-19 Nutraceuticals for Patients with Cancer
  37. Emerging roles for stress kinase p38 and stress hormone fibroblast growth factor 21 in NAFLD development
  38. Understanding the enigmatic association between mycosis fungoides and psoriasis: Report of two cases and review of the literature
  39. Circulating Omentin-1 as a Biomarker at the Intersection of Postmenopausal Breast Cancer Occurrence and Cardiometabolic Risk: An Observational Cross-Sectional Study
  40. The glycemic status determines the direction of the relationship between red cell distribution width and HbA1c
  41. Vitamin D and parathyroid hormone in critically ill septic patients: a prospective study
  42. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity*
  43. The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era
  44. Diabetes Mellitus and SARS-CoV-2 Infection: Pathophysiologic Mechanisms and Implications in Management
  45. Diabetes mellitus in the era of climate change
  46. Mycobiome and Cancer: What Is the Evidence?
  47. Circulating leptin, soluble leptin receptor and free leptin index in critically ill patients with sepsis: a prospective observational study
  48. Serum bilirubin to fetuin-A ratio as a prognostic biomarker in critically ill patients with sepsis
  49. Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic
  50. Prediabetes screening: Questionable benefits in the golden years
  51. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
  52. Do Antibiotics Cause Obesity Through Long-term Alterations in the Gut Microbiome? A Review of Current Evidence
  53. Understanding the Co-Epidemic of Obesity and COVID-19: Current Evidence, Comparison with Previous Epidemics, Mechanisms, and Preventive and Therapeutic Perspectives
  54. The Role of Mitochondrial Adaptation and Metabolic Flexibility in the Pathophysiology of Obesity and Insulin Resistance: an Updated Overview
  55. Vitamin D and Obesity: Current Evidence and Controversies
  56. Diabetes type 1: Can it be treated as an autoimmune disorder?
  57. Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma
  58. Efficacy of Dietary Manipulations for Depleting Intrahepatic Triglyceride Content: Implications for the Management of Non-alcoholic Fatty Liver Disease
  59. Gender Differences in Obesity-Related Cancers
  60. Adherence to the Mediterranean diet is an independent predictor of circulating vitamin D levels in normal weight and non-smoker adults: an observational cross-sectional study
  61. The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19
  62. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?
  63. Does COVID-19 Involve the Retina?
  64. Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives
  65. Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real‐world setting
  66. Covid-19 and Disparities in Nutrition and Obesity
  67. Alterations in serum lipid profile in critically ill septic patients: a prospective study
  68. C-reactive protein/albumin ratio as a prognostic biomarker in critically ill septic patients: a prospective study
  69. Serum bilirubin/fetuin-A ratio in critically ill septic patients: a prospective study
  70. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19
  71. The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity
  72. Autoantibody Production in Obesity: Is There Evidence for a Link Between Obesity and Autoimmunity?
  73. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?
  74. Is There an Obesity Paradox in Critical Illness? Epidemiologic and Metabolic Considerations
  75. Probiotics, Prebiotics, Synbiotics, Postbiotics, and Obesity: Current Evidence, Controversies, and Perspectives
  76. Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations
  77. The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
  78. How does the joint dermatology–rheumatology clinic benefit both patients and dermatologists?
  79. Sarcopenic Obesity: Epidemiologic Evidence, Pathophysiology, and Therapeutic Perspectives
  80. The Role of Adipokines in Breast Cancer: Current Evidence and Perspectives
  81. The Role of Adipose Tissue and Adipokines in Sepsis: Inflammatory and Metabolic Considerations, and the Obesity Paradox
  82. Circulating total leptin as a diagnostic and prognostic biomarker in sepsis
  83. Classic and Novel Adipokines as diagnostic biomarkers in NSCLC
  84. Chemerin and PAI-1 activity as diagnostic biomarkers in resectable NSCLC:comparison to classic tumour markers
  85. Diverting epithelial-to-mesenchymal transition to transform cancer cells to adipocytes: A promising strategy to stop metastasis
  86. Could hyperglycemia-induced cardiac autoimmunity be hidden behind cardiovascular disease in type 1 diabetes mellitus?
  87. Mitochondrial glycerol 3-phosphate dehydrogenase deficiency aggravates hepatic triglyceride accumulation and steatosis
  88. Circulating eNampt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis: A prospective observational study
  89. Effect of heterozygous beta thalassemia on HbA1c levels in individuals without diabetes mellitus: A cross sectional study
  90. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives
  91. Adherence to the Mediterranean diet is independently associated with psoriasis risk, severity, and quality of life: a cross‐sectional observational study
  92. Can we better strategize our choice of pharmacotherapy for patients with co-morbid psoriasis and obesity?
  93. Professor Xenophon J Contiades: The most significant medical loss during World War II in Greece
  94. Early menarche is independently associated with subclinical hypothyroidism: a cross-sectional study
  95. What are the key points in the association between the gut microbiome and nonalcoholic fatty liver disease?
  96. Metabolism Open: A new journal in the quest of the golden fleece in metabolic research
  97. Obesity and cancer risk: Emerging biological mechanisms and perspectives
  98. Could the endocrine disruptor bisphenol-A be implicated in the pathogenesis of oral and oropharyngeal cancer? Metabolic considerations and future directions
  99. Comment to: Are fetuin-A levels beneficial for estimating timing of sepsis occurrence?
  100. Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer
  101. eNAMPT as a novel diagnostic and prognostic biomarker in critically ill septic patients
  102. Resistin may predict severity and mortality in critically ill septic patients
  103. Circulating eNAMPT and resistin as emerging biomarkers in sepsis
  104. Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies
  105. The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges
  106. Fetuin-A to adiponectin ratio is a promising prognostic biomarker in septic critically ill patients
  107. Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors
  108. Kinetics of circulating fetuin-A may predict mortality independently from adiponectin, high molecular weight adiponectin and prognostic factors in critically ill patients with sepsis: A prospective study
  109. Kinetics of serum adiponectin and HMWA (High Molecular Weight Adiponectin), and mortality in ICU patients with sepsis
  110. Circulating fetuin-A as a biomarker predicting mortality in ICU septic patients
  111. Psoriasis is associated with risk of obstructive sleep apnea independently from metabolic parameters and other comorbidities: a large hospital-based case-control study
  112. Visfatin, Obesity, and Cancer
  113. Prevalence of psoriatic arthritis and its correlates among patients with psoriasis in Greece: results from a large retrospective study
  114. Polymorphous light eruption under the Mediterranean sun: a clinico-epidemiological and photobiological study
  115. Circulating resistin is a significant predictor of mortality independently from cardiovascular comorbidities in elderly, non-diabetic subjects with chronic kidney disease
  116. Cedecea
  117. Fetuin-A levels and free leptin index are reduced in patients with chronic lymphocytic leukemia: a hospital-based case-control study
  118. 1C.09
  119. Adiponectin as a biomarker linking obesity and adiposopathy to hematologic malignancies
  120. Association of clinicopathological characteristics with secondary neoplastic lymphoproliferative disorders in patients with lymphomatoid papulosis
  121. Circulating fetuin-A in patients with pancreatic cancer: a hospital-based case-control study
  122. Uncovering the life and work of Louis Tribondeau: a pioneer in dermatology and biochemistry
  123. Validation of a Real-Time Quantitative Polymerase Chain Reaction Method for the Quantification of 3 Survivin Transcripts and Evaluation in Breast Cancer Tissues
  124. Kinetics of serum ischemia-modified albumin during cardiopulmonary exercise testing in relation to metabolic and cardiac markers: A pilot study
  125. Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis?
  126. Reply to: Pityriasis rosea and pityriasis rosea–like eruptions
  127. Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives
  128. Ustekinumab Induces Fast Response and Maintenance of Very Severe Refractory Scalp Psoriasis: Results in Two Greek Patients from the Psoriasis Hospital-Based Clinic
  129. Sideritis euboea extract lowers total cholesterol but not LDL cholesterol in humans: a randomized controlled trial
  130. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome
  131. Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: A prospective controlled study
  132. Correction
  133. A new hypofractionated schedule of weekly irradiation for basal cell carcinoma of the head and neck skin area in elderly patients
  134. Remembering Louis Tribondeau (1872-1918)
  135. Hyperresistinemia is associated with postmenopausal breast cancer
  136. Leptin at the Intersection of Neuroendocrinology and Metabolism: Current Evidence and Therapeutic Perspectives
  137. Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals
  138. Serum resistin: A biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters
  139. Adipocytokines and psoriasis: Insights into mechanisms linking obesity and inflammation to psoriasis
  140. Correlates of Serum Resistin in Elderly, Non-Diabetic Patients with Chronic Kidney Disease
  141. Metabolic co-morbidities and psoriasis: The chicken or the egg?
  142. Nomenclature and Basic Concepts in Automation in the Clinical Laboratory Setting: A Practical Glossary
  143. Nicotinamide phosphoribosyl-transferase/visfatin: A missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges
  144. Lobomycosis: A case from Southeastern Europe and review of the literature
  145. The Role of Adiponectin in Cancer: A Review of Current Evidence
  146. Unmasking the Janus face of the association between psoriasis, metabolic syndrome and obstructive sleep apnea
  147. Prevalence of non classical congenital adrenal hyperplasia due to 21‐hydroxylase deficiency in Greek women with acne: a hospital‐based cross‐sectional study
  148. Sleep apnea as a comorbidity in obese psoriasis patients: a cross‐sectional study. Do psoriasis characteristics and metabolic parameters play a role?
  149. Could serum visfatin be a potential biomarker for postmenopausal breast cancer?
  150. A life-threatening case of disseminated nocardiosis due to Nocardia brasiliensis
  151. Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters
  152. Serum adiponectin and leptin in relation to risk for preeclampsia: results from a large case-control study
  153. Serum levels of ischemia modified albumin in overweight/obese postmenopausal women: A potential biomarker of atherosclerotic burden associated with oxidative stress
  154. 538 ISCHEMIA MODIFIED ALBUMIN (IMA) IN POSTMENOPAUSAL WOMEN WITH OR WITHOUT CORONARY ARTERY DISEASE (CAD) IN RELATION TO BMI AND OGTT
  155. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR
  156. The Association Between a CommonFCGR2APolymorphism and C-Reactive Protein and Coronary Artery Disease Revisited
  157. Familial occurrence of calcifying epithelioma of Malherbe
  158. Adipocyte factors, high-sensitive C-reactive protein levels and lipoxidative stress products in overweight postmenopausal women with normal and impaired OGTT
  159. P374 EPIGENETIC MODIFICATIONS IN HUMAN CAROTID ATHEROMATOUS PLAQUES
  160. MS90 ADIPOCYTE FACTORS, hsCRP AND MALONDIALDEHYDE LEVELS IN OVERWEIGHT POSTMENOPAUSAL WOMEN WITH NORMAL AND IMPAIRED OGTT
  161. B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case–control study in Greece
  162. Cutaneous involvement in angioimmunoblastic T-cell lymphoma
  163. Platelet Markers Correlate with Glycemic Indices in Diabetic, but Not Diabetic-Myelodysplastic Patients with Normal Platelet Count
  164. Ischemia modified albumin, high-sensitivity c-reactive protein and natriuretic peptide in patients with coronary atherosclerosis
  165. Circulating oxidized LDL levels, current smoking and obesity in postmenopausal women
  166. Isolation of Leclercia adecarboxylata from blood and burn wound after a hydrofluoric acid chemical injury
  167. Recall injection-site reactions to etanercept in a patient with psoriasis
  168. TCRVb repertoire abnormalities in patients with cutaneous T-cell lymphoma
  169. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study
  170. Cedecea lapagei bacteremia following cement-related chemical burn injury
  171. Orchiépididymite et bactériémie à Leclercia adecarboxylata
  172. Cutaneous abscess and bacteremia due to Serratia ficaria
  173. Association of serum complement and platelet parameters with Escherichia coli bacteraemia: A cross-sectional study
  174. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case–control study
  175. Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system
  176. Serum oxidizability, total antioxidant status and albumin serum levels in patients with aneurysmal or arterial occlusive disease
  177. Hypocalcemia, Hypomagnesemia, and Hypokalemia Following Hydrofluoric Acid Chemical Injury
  178. OXIDIZED LDL AND POSTMENOPAUSAL OBESITY
  179. Leptin, soluble leptin receptor, adiponectin and resistin in relation to OGTT in overweight/obese postmenopausal women
  180. Association of thyroid disease and thyroid autoimmunity with multiple myeloma risk: A case–control study
  181. How to Manage Melanoma in a Psoriatic Patient
  182. Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci
  183. Subcutaneous Sarcoidosis Masquerading as Cellulitis
  184. Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients
  185. Is thyroid autoimmunity a risk factor for developing primary myelodysplastic syndrome?
  186. Oxidized LDL, serum oxidizability and serum lipid levels in patients with breast or ovarian cancer
  187. Palmoplantar and scalp psoriasis occurring during anti–tumour necrosis factor‐α therapy: a case series of four patients and guidelines for management
  188. PO19-521 ASSOCIATION OF ADIPONECTIN WITH HDL AND TRIGLYCERIDES SERUM LEVELS IN WOMEN WITH NORMAL AND IMPAIRED OGTT
  189. P1833 A cost-effective study of VRE surveillance in a Greek university hospital
  190. P1697 Reduced rates of vancomycin-resistant enterococci coloni-sation after implementation of infection control measures
  191. Circulating Adiponectin and Leptin in Relation to Myelodysplastic Syndrome: A Case-Control Study
  192. Spontaneous peritonitis caused by Leminorella grimontii
  193. Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics
  194. Clinical study on the serum carcinoembryonic antigen, CA 19-9, CA 50 and α-fetoprotein levels in patients with myelodysplastic syndromes
  195. Small doses of LH activity are needed early in ovarian stimulation for better quality oocytes in IVF-ET
  196. Association of Hyperandrogenemic and Metabolic Phenotype with Carotid Intima-Media Thickness in Young Women with Polycystic Ovary Syndrome
  197. Home and leisure activities and childhood knee injuries
  198. Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease
  199. Pseudomonas fluorescens cutaneous abscess and recurrent bacteremia following a dog bite
  200. The significance of oxidant/antioxidant balance for the pathogenesis of experimental sepsis by multidrug-resistant Pseudomonas aeruginosa
  201. Experimental sepsis using Pseudomonas aeruginosa: the significance of multi-drug resistance
  202. Pseudomonas luteola Cutaneous Abscess and Bacteraemia in a Previously Healthy Man
  203. Rapid alterations of serum fatty acids with the intravenous administration of an arachidonate solution
  204. Adiponectin and Breast Cancer Risk
  205. Generalized infection associated with ECHO virus
  206. Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study
  207. Coexistence of Primary Refractory Anemia with Ringed Sideroblasts and T Cell-Lymphoblastic Non-Hodgkin Lymphoma
  208. Frequency and Nature of Recorded Childhood Immunization‐Related Errors in Greece
  209. Fusobacterium necrophorum septicemia following Epstein-Barr virus infectious mononucleosis
  210. Stenotrophomonas maltophilia: a serious and rare complication in patients suffering from burns
  211. A cluster analysis of road traffic‐related childhood knee injuries
  212. Lipid peroxidation in chronic gastritis; any influence of Helicobacter pylori?
  213. Ex vivo synergy of arachidonate-enriched serum with ceftazidime and amikacin on multidrug-resistant Pseudomonas aeruginosa
  214. Serum Apolipoprotein AI Levels in Atherosclerotic and Diabetic Patients
  215. Rapid alterations of serum oxidant and antioxidant status with the intravenous administration of n-6 polyunsaturated fatty acids
  216. Impact of n-6 Polyunsaturated Fatty Acids on Growth of Multidrug-Resistant Pseudomonas aeruginosa: Interactions with Amikacin and Ceftazidime
  217. Human neutral brush border endopeptidase EC 3.4.24.11 in urine, its isolation, characterisation and activity in renal diseases
  218. Serum Lp(a) Lipoprotein Levels in Patients with Atherosclerotic Occlusive Disease of the Lower Extremities
  219. Variations of serum hormone levels in young exercising women
  220. Steroid hormones and lipoproteins
  221. In vitro interactions of γ‐Linolenic acid and arachidonic acid with ceftazidime on multiresistantPseudomonas aeruginosa
  222. In vitro activity of polyunsaturated fatty acids on Pseudomonas aeruginosa: relationship to lipid peroxidation
  223. In vitro influence of polyunsaturated fatty acids on nosocomial Pseudomonas aeruginosa: a preliminary report
  224. In-vitro inhibitory activity of gamma-linolenic acid on Escherichia coli strains and its influence on their susceptibilities to various antimicrobial agents
  225. Follicular fluid inhibin levels in relation to age in patients in an in vitro fertilization and embryo transfer programme
  226. Endogenous testosterone and serum apolipoprotein(a) levels
  227. Changes in serum lipids in rats treated with PGF2a
  228. Postnatal changes of cathepsin D activity in rat liver and brain
  229. The effect of hashish-smoking on serum levels of pancreatic lipase (ec 3.1.1.3) in man
  230. Influence of prostaglandin E1 on high density lipoprotein-fraction lipid levels in rats
  231. Lipid levels in high density lipoprotein subfractions in smokers with peripheral vascular disease
  232. Level of plasma fibronectin in patients with peripheral vascular disease
  233. Changes of HDL-lipid composition as related to Δ9-THC action
  234. Determination of proteolytic activity using l-[4,5-3h]leucine-labelled globin as a substrate
  235. Activation of cathepsin D by glycine ethyl ester
  236. The possible effect of hashish on leukocytes and plasma lipids
  237. Metabolism of methylated analogs of aldrin and dieldrin by liver preparations from male and female rat
  238. Inactivation of cathepsin D from human gastric mucosa and from stomach carcinoma by diazoacetyl-dl-norleucine methyl ester